This invention relates to a series of binuclear palladacycle compounds, and methods for the production of these compounds, that are suitable for use in the treatment of cancer. In particular embodiments, R.sup.1 is phenyl substituted with two occurrences of isopropyl, R.sup.2 is Cl, and R.sup.3 is independently one or more substituents selected from —O(CH.sub.2).sub.2O(CH.sub.2).sub.2OH, —O(CH.sub.2).sub.2O(CH.sub.2).sub.2O(CH.sub.2).sub.2OH, —O(CH.sub.2).sub.2OH, and —O(CH.sub.2).sub.2O(CH.sub.2).sub.2OCH.sub.3.

The invention relates to compounds of formula (I)

##STR00001##

where R.sup.1, R.sup.2, R.sup.3, R.sup.4 are each independently selected from —(C.sub.1-C.sub.12)-alkyl, —(C.sub.3-C.sub.12)-cycloalkyl, —(C.sub.3-C.sub.12)-heterocycloalkyl, —(C.sub.6-C.sub.20)-aryl, —(C.sub.3-C.sub.20)-heteroaryl; at least one of the R.sup.1, R.sup.2, R.sup.3, R.sup.4 radicals is a —(C.sub.3-C.sub.20)-heteroaryl radical; and R.sup.1, R.sup.2, R.sup.3, R.sup.4, if they are —(C.sub.1-C.sub.12)-alkyl, —(C.sub.3-C.sub.12)-cycloalkyl, —(C.sub.3-C.sub.12)-heterocycloalkyl, —(C.sub.6-C.sub.20)-aryl or —(C.sub.3-C.sub.20)-heteroaryl, may each independently be substituted by one or more substituents selected from —(C.sub.1-C.sub.12)-alkyl, —(C.sub.3-C.sub.12)-cycloalkyl, —(C.sub.3-C.sub.12)-heterocycloalkyl, —O—(C.sub.1-C.sub.12)-alkyl, —O—(C.sub.1-C.sub.12)-alkyl-(C.sub.6-C.sub.20)-aryl, —O—(C.sub.3-C.sub.12)-cycloalkyl, —S—(C.sub.1-C.sub.12)-alkyl, —S—(C.sub.3-C.sub.12)-cycloalkyl, —COO—(C.sub.1-C.sub.12)-alkyl, —COO—(C.sub.3-C.sub.12)-cycloalkyl, —CONH—(C.sub.1-C.sub.12)-alkyl, —CONH—(C.sub.3-C.sub.12)-cycloalkyl, —CO—(C.sub.1-C.sub.12)-alkyl, —CO—(C.sub.3-C.sub.12)-cycloalkyl, —N—[(C.sub.1-C.sub.12)-alkyl].sub.2, —(C.sub.6-C.sub.20)-aryl, —(C.sub.6-C.sub.20)-aryl-(C.sub.1-C.sub.12)-alkyl, —(C.sub.6-C.sub.20)-aryl-O—(C.sub.1-C.sub.12)-alkyl, —(C.sub.3-C.sub.20)-heteroaryl, —(C.sub.3-C.sub.20)-heteroaryl-(C.sub.1-C.sub.12)-alkyl, —(C.sub.3-C.sub.20)-heteroaryl-O—(C.sub.1-C.sub.12)-alkyl, —COOH, —OH, —SO.sub.3H, —NH.sub.2, halogen; and to the use thereof as ligands in alkoxycarbonylation.

Triaryl phosphine ligands, as shown in general formulae Ia and Ib, or a mixture thereof, and a preparation method therefor. The invention addresses the deficiencies of biaryl phosphine ligands invented by Buchwald et al. Also provided are a triaryl phosphine coordinated palladium complex, a system composed of triaryl phosphine ligand and a palladium salt or complex, and a use of the triaryl phosphine coordinated palladium complex in catalysing organic reactions, in particular a use in catalysis of coupling reactions involving (pseudo)halogenated aromatic hydrocarbon as substrate.

Provided are triaryl phosphine ligands, as shown in general formulae Ia and Ib, or a mixture thereof, and a preparation method therefor. The invention addresses the deficiencies of biaryl phosphine ligands invented by Buchwald et al. Also provided are a triaryl phosphine coordinated palladium complex, a system composed of triaryl phosphine ligand and a palladium salt or complex, and a use of the triaryl phosphine coordinated palladium complex in catalysing organic reactions, in particular a use in catalysis of coupling reactions involving (pseudo)halogenated aromatic hydrocarbon as substrate.

An object of the present invention is to provide a novel method for producing an α-fluoroacrylic acid ester compound. ##STR00001##
This problem is solved by a method for producing a compound represented by formula (1), wherein R.sup.1 and R.sup.2 are identical or different, and each represents an alkyl group or the like; and R.sup.3 is an alkyl group or the like, the method comprising step A of reacting a compound represented by formula (2) with R.sup.3—OH (3) and carbon monoxide in the presence of palladium, a double bond-containing compound (α), a diphosphine compound (β), and a base, to obtain the compound represented by formula (1) above.

The present disclosure provides methods of making confined nanocatalysts within mesoporous materials (MPMs). The methods utilize solid state growth of nanocrystalline metal organic frameworks (MOFs) followed by controlled transformation to generate nanocatalysts in situ within the mesoporous material. The disclosure also provides applications of the nanocatalysts to a wide variety of fields including, but not limited to, liquid organic hydrogen carriers, synthetic liquid fuel preparation, and nitrogen fixation.

Provided are organometallic compounds of of Formula I:

##STR00001##

Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

A phosphorescent compound of formula (I): ##STR00001##
wherein: M is a transition metal; C.sup.1 is a carbon atom forming a metal-carbene bond with M; A is a saturated bridged bicyclic or saturated bridged tricyclic group consisting of one nitrogen atom and 6-12 carbon atoms; either: (i) X.sup.1 is a bridgehead carbon atom of the bridged bicyclic or bridged tricyclic group and X.sup.2 is NR.sup.1 wherein R.sup.1 is a substituent, or (ii) X.sup.1 is N and X.sup.2 is a bridgehead group of formula CR.sup.6 wherein R.sup.6 is H or a substituent; Ar.sup.1 is a C.sub.6-20 aromatic group or a 5-20 membered heteroaromatic group; L in each occurrence is independently a mono- or poly-dentate ligand other than a ligand of formula A-Ar.sup.1; x is at least 1; and y is 0 or a positive integer. The compound of formula (I) may be used as a blue light-emitting material in a white organic light-emitting device.

The present invention relates to ligands based on calixarenes, metal complexes comprising such ligands and their use as homogeneous or heterogeneous catalysts.

Compounds of General Formula I may act electron transporting materials, hole blocking materials, and host materials. Devices incorporating compounds of General Formula I may have exhibit device performance characteristics.

##STR00001##